Postoperative Assessment of Platelet-Rich Plasma and Platelet-Rich Fibrin in Temporomandibular Joint Surgery

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Jingping Wang, MD, Ph.D.
Study ID
NCT07359131
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Temporomandibular Joint Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Study Details

The goal of this observational study is to evaluate postoperative outcomes following temporomandibular joint (TMJ) surgery and to compare the effectiveness of intraoperative platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) injections in patients with temporomandibular joint disorders. The study includes adult patients who underwent TMJ surgery and received either PRP or PRF intraoperatively. The main questions this study aims to answer are: Whether intraoperative PRP or PRF injection is associated with differences in postoperative pain intensity and recovery. Whether PRP and PRF differ in their effects on postoperative jaw function, including maximum mouth opening and joint symptoms. If there is a comparison group: Researchers will compare patients who received intraoperative PRP with those who received intraoperative PRF to assess differences in postoperative pain, functional outcomes, and joint-related symptoms. Participants will: Have their existing medical records reviewed retrospectively. Provide postoperative outcome data derived from routine clinical follow-up, with no prospective recruitment or intervention.

Key Dates

Start date
Nov 15, 2026
Status verified
Jan 2026
Primary completion
Oct 31, 2027
Completion
Dec 5, 2027

Study Design

Enrollment
700 participants (estimated)

Arms

  • Arm: Group 1 - Platelet-Rich Plasma injection therapy group
    Patients who received Platelet-Rich Plasma injections during surgery.
  • Arm: Group 2 - Platelet-Rich Fibrin injection therapy group
    Patients who are receiving Platelet-Rich Fibrin injections during surgery.
  • Arm: Group 3 - non injection therapy group
    Patients who are not receiving Platelet-Rich Plasma nor Platelet-Rich Fibrin injections during surgery.

Primary Outcome Measure

pain intensity [ Time Frame: from baseline to 6 months post-surgery. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Meikun WangBostonMassachusetts02114-

Find similar trials in Boston, MA

By research site
Meikun Wang· Boston, MA

Related Studies